---
title: "Cerus Corp 1Q 2026: Revenue $59.9M, EPS $(0.01) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284837799.md"
description: "Cerus Corp reported Q1 2026 results with revenue of $59.9M, a 23% increase year-over-year, and a narrowed net loss of $1.64M compared to $7.72M in Q1 2025. Diluted EPS was $(0.01). Revenue growth was driven by a 24% rise in product sales, particularly in disposable platelet kits. The company is shifting sales strategy towards IFC kits for blood centers. Operational challenges affected gross margins, and inventory was increased to meet demand. Regulatory progress includes advancements in red blood cell system development and contract revenue growth under BARDA agreements."
datetime: "2026-04-30T21:11:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284837799.md)
  - [en](https://longbridge.com/en/news/284837799.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284837799.md)
---

# Cerus Corp 1Q 2026: Revenue $59.9M, EPS $(0.01) — 10-Q Summary

Cerus Corp reported first-quarter 2026 results with revenue of $59.9M, up 23% year-over-year, and a net loss narrowed to $1.64M versus a $7.72M loss in the year-ago quarter; diluted EPS was $(0.01) for the quarter.

**Financial Highlights**

-   Revenue: $59.9M for Q1 2026, up from $48.9M in Q1 2025 (23% YoY).
-   Net income: Net loss attributable to Cerus Corporation of $(1.64) M for Q1 2026, improved from a net loss of $(7.72) M in Q1 2025.
-   Diluted EPS: $(0.01) for Q1 2026, versus $(0.04) in Q1 2025.

**Business Highlights**

-   Revenue growth was driven by a 24% increase in product sales, led by disposable platelet kits and growth in IFC kit sales.
-   Company is accelerating a channel shift toward IFC kit sales to blood centers and away from direct hospital sales, supporting recurring kit demand.
-   Regulatory and R&D progress includes continued red blood cell system development; ReCePI reported positive topline results, RedeS enrollment completed, though additional trials may be required.
-   Increased activity under the 2024 BARDA Agreement and DoD work boosted contract revenue; a separate 2016 BARDA program is scheduled to end in September 2026.
-   Operational pressures compressed gross margins due to tariffs, freight, FX and inflation, and the company built inventory to meet forecasted demand.

Original SEC Filing: CERUS CORP \[ CERS \] - 10-Q - Apr. 30, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [CERS.US](https://longbridge.com/en/quote/CERS.US.md)

## Related News & Research

- [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md)
- [Hafnia’s Q1 2026 Financial Results Presentation to Be Held on 27 May 2026 | HAFN Stock News](https://longbridge.com/en/news/287014236.md)
- [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md)
- [Keysight Technologies Reports Second Quarter 2026 Results | KEYS Stock News](https://longbridge.com/en/news/286959830.md)
- [Wide postpones 2026 annual meeting to June 17; proxy voting deadline June 16](https://longbridge.com/en/news/286911986.md)